1. Starting points for the development of new targeted therapies for glioblastoma multiforme
- Author
-
Agnieszka Rusak, Benita Wiatrak, Klaudia Krawczyńska, Tomasz Górnicki, Karol Zagórski, Łukasz Zadka, and Wojciech Fortuna
- Subjects
Glioblastoma ,Targeted therapy ,Chemoresistance phenotype ,Anticancer treatment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal brain tumors, characterized by rapid growth, invasiveness, and resistance to standard therapies, including surgery, chemotherapy, and radiotherapy. Despite advances in treatment, GBM remains highly resistant due to its complex molecular mechanisms, including angiogenesis, invasion, immune modulation, and lipid metabolism dysregulation. This review explores recent breakthroughs in targeted therapies, focusing on innovative drug carriers such as nanoparticles and liposomes, and their potential to overcome GBM's chemo- and radioresistant phenotypes. We also discuss the molecular pathways involved in GBM progression and the latest therapeutic strategies, including immunotherapy and precision medicine approaches, which hold promise for improving clinical outcomes. The review highlights the importance of understanding GBM's genetic and molecular heterogeneity to develop more effective, personalized treatment protocols aimed at increasing survival rates and enhancing the quality of life for GBM patients.
- Published
- 2025
- Full Text
- View/download PDF